MétaCan
Menu
Back to cohort

Clinical activity of celecoxib (CXB) in metastatic malignant melanoma (MMM)

2005· article· en· W2249582782 on OpenAlexaffabout
Kenneth S. Wilson, Sharon J. Allan

Bibliographic record

VenueJournal of Clinical Oncology · 2005
Typearticle
Languageen
FieldMedicine
TopicInflammatory mediators and NSAID effects
Canadian institutionsIsland Health
Fundersnot available
KeywordsMedicineCelecoxibGastroenterologyCancerMelanomaInternal medicineSurgeryOncologyPathologyCancer research

Abstract

fetched live from OpenAlex

7555 Background: COX-2 is demonstrable by IHC in most primary MM, and by mRNA/protein studies in MM cell lines (Denkert, Cancer Res., 2001). Effects of COX-2 therapy (Rx) in MM include decreased endothelial cell migration, dose/time dependent decreases in invasiveness and collagenase IV production, fewer lung metastases post i.v. tumor cell inj., and reduced Matrigel invasion in MM cell lines. Analyses of COX-2 expression during melanoma progression suggest that COX-2 has a functional role (Goulet et al, Cancer Biol Ther., 2003). Following the observed regression (?“spontaneous”) of lung metastases in a MMM pt who received CXB for acute gout (http://bmj.bmjjournals.com/cgi/eletters/325/7371/26644), CXB was offered to suitable pts. who had either no/minor symptoms, or had failed other Rx. CXB is presently approved by Health Canada for familial adenomatous polyposis coli. Methods: Eligibility; age >16 yrs, surgically incurable recurrent MM. Pts. with prior IFN (adjuvant), RT, chemoRx (CT), BioCT were included. Treatment; CXB 200mg daily, Rofecoxib 12.5mg daily for 1 sulfa-allergic pt., and continued until progression (PD). Results: From May 2000 to Aug 2004, 24 pts (7 F, 17 M), 22 cutaneous, 1 anal canal, 1 choroidal MM, median age 58.4 yrs (range 24 - 85), distant mets. (N = 23), unresectable regional mets. (N = 1), were treated. Median diameter of largest metastasis was 31 mm (range 0 - 110) at start of CXB (0 = non measurable pleural effusion). Median follow-up time for living pts. is 10.3 mo. (range 3.6 - 55.2). Prior therapy; RT (N = 8), DTIC (N = 4), IFN (N = 2), BioCT (N = 1), no prior Rx (N = 12), no prior systemic Rx (NPSRx, N = 16). Two pts. were CXB - intolerant and stopped within 2 wks. Tumor regressions were seen in 5 pts; 2 CR in small volume lung mets. (1 had previous Cancervax then BioCT, 1 NPSRx), mixed stable/PR in 3 NPSRx pts. (1 bulky metastatic choroidal MM, 1 multiple lung mets., 1 bilat. neck nodes) [images to be presented]. For all pts., median survival time (MST) from first incurable metastasis was 12.7 mo., and median times to PD and MST from start of CXB were 3.3 mo. and 8.1 mo. respectively. Conclusion: CXB has clinical activity and merits further evaluation with parallel study of COX-2 expression in MMM to investigate its biologic basis. No significant financial relationships to disclose.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.126
GPT teacher head0.485
Teacher spread0.359 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2005
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicInflammatory mediators and NSAID effectsFrench-language works237,207